Increased longevity and quality of life are ancient longings of human societies, but never like today were they so pressing. The fulfilment of such desires is BSIM2‘s reason to exist, its vital breath, its ultimate purpose. The discovery and optimization of new drug candidates that can answer those desires is the company’s primary goal. BSIM2 aims to become a leading company in the application of structural bioinformatics and chemoinformatics towards the development of new therapies, working alongside pharmaceutical and biotechnology industries.


Business Model

Licensing of intellectual property rights and joint-venture agreements for the development of new drug candidates.



BSIM2 is a spin-off company founded in 2011 as the result of scientific work carried out at the University of Coimbra, in collaboration with the University of Leeds. For five years, the promoters assembled a suite of computational algorithms and workflows to conduct large-scale screenings and identify new amyloid inhibitors. The first product of the company’s portfolio is directed against a rare and fatal neurodegenerative disease.




Carlos J. V. Simoes, PharmD, PhD

Co-founder and Chief Technology Officer

Carlos Simoes earned his PharmD and his PhD from the University of Coimbra (UC). He has been a collaborator at the Centro de Estudos Farmaceuticos (at UC), visiting researcher at the Istituto di Chimica del Riconoscimento Molecolare, in Italy, and PhD student at the Center for Neuroscience and Cell Biology (at UC). During his PhD studies, he spent three years working with the Bioinformatics group of the Institute of Molecular and Cellular Biology of the University of Leeds, in the United Kingdom. More recently, he was a research fellow at PRACE, the Partnership for Advanced Computing in Europe. In the several projects he has been involved in, he has worked on multiple computational approaches to study biological systems, with particular attention to protein dynamics, protein-ligand and protein-protein interactions, exploring virtual screening and rational drug design approaches. Carlos Simoes has published several scientific papers in international peer-reviewed journals and was the receiver of the “Connecting Science to People” award in 2010, promoted by the Portuguese Society of Biochemistry and the company Take the Wind. At present, Carlos Simoes is manager and Chief Technology Officer (CTO) at BSIM2.

Rui M. M. Brito, BSc, PhD

Co-founder and Chief Science Officer

Rui Brito is Associate Professor at the Chemistry Department of the Faculty of Sciences and Technology of the University of Coimbra (UC) and Principal Investigator of the Center for Neuroscience and Cell Biology (at UC). He holds a BSc in Biochemistry from the UC, and a PhD in Biochemistry from Rice University, Houston, USA. He carried out post-doctoral studies at the Oxford Centre for Molecular Sciences, Oxford University, UK, and since then has been visiting scientist at the University of Cincinnati and Johns Hopkins University, USA, and the Leibniz-Institut fur Molekulare Pharmakologie, in Berlin, Germany. Rui Brito has dedicated his scientific career to the study of protein structure, stability, folding and aggregation, with special emphasis on the molecular mechanisms of neurodegenerative amyloid pathologies. He has published more than 50 peer-reviewed scientific papers in international journals. Presently, Rui Brito leads the Structural and Computational Biology group at the CNC, where he supervises a team of 10 researchers. He is director of the NMR spectroscopy platform at UC and member of the scientific board of the NMR national network (PTNMR). He is also the National Coordinator of the Ibercivis volunteer computing platform, and member of the Executive Committee of the Portuguese Center for Integrated Structural Biology – INSTRUCT Affiliate Center for Portugal. Currently, Rui Brito is manager and Chief Science Officer (CSO) at BSIM2.

Bruno L. Victor, BSc, PhD

Biomolecular Simulations Expert

Bruno Victor holds a BSc in Biochemistry by the Faculty of Sciences and Technology from the University of Coimbra and a PhD in Biochemistry by Institute of Biology and Chemistry technology (ITQB) from the New University of Lisbon. Throughout his PhD and Post-Doc he developed work in molecular modelling and structural bioinformatics areas becoming expert in several theoretical and computational methodologies such as molecular mechanics, protein-protein and protein-ligand interactions and protein structure prediction. During these years he has published several scientific papers in international peer-reviewed journals and was an active member in non-funded scientific associations such as the Portuguese Biophysical Society and more recently the Portuguese Biochemical Society. Currently, Bruno Victor is a full-time research scientist at BSIM2.



Maria Joao Saraiva, BSc, MSc, PhD

Amyloid Research

Maria Joao Saraiva is Group Leader of the Molecular Neurobiology group of the Institute for Molecular and Cell Biology (IBMC) and Full Professor at Universidade do Porto (UP), Portugal. She received a BSc degree in Biology from the University of Porto (UP), a MSc degree in Biochemistry from the University of London, United Kingdom, and a PhD in Biochemistry from UP. Maria Joao Saraiva is a recognized leader in the field of neurodegenerative diseases, in particular, the Familial Amyloidotic Polyneurophaty (FAP) and amyloid plaques formation. She has always been involved in the research of biochemical and genetic mechanisms responsible for transthyretin-related amyloidoses, but also the clinical aspects of the resulting pathologies. Maria Joao Saraiva has been coordinating several top international projects and has numerous important publications in international journals. In 2009, she was the receiver of the Gulbenkian Science Award.

Sergio Simoes, PharmD, MSc, PhD

Pharmaceutical Development

Sergio Simoes has a degree in Pharmaceutical Sciences, a Master degree in Engineering Sciences and a PhD in Pharmaceutics. He holds a position as assistant professor at Faculty of Pharmacy of the University of Coimbra (UC), Portugal. Sergio Simoes is Member of the Board and Vice-president for business and product development of Bluepharma, and a research member at the Center for Neurosciences and Cell Biology (at UC). His research activity has been focused on the development of targeted nanocarriers for drug and nucleic acid delivery aiming at their application for gene therapy. He has published more than 70 SCI journal papers, 7 book chapters, 5 patents (1 granted, 4 pending) and he is the author/co-author of 235 presentations in international conferences and workshops. Over the last years, Sergio Simoes has conducted several research projects in the field of Biotechnology and gained significant expertise on the development, industrial transfer and manufacturing of pharmaceutical dosage forms for the European and US market.